A 48-year-old man was referred with an asymptomatic skin lesion on his left shoulder. On examination there was a circumscribed patch, 20620 cm in size, with ®rm follicular papules (Fig. 2) . According to the patient these asymptomatic lesions had been there since birth. There was no hyperpigmentation and the pseudo Darier sign was negative.
Histology showed numerous bundles of smooth muscles in the middermis, mostly unattached to the hair follicles (Fig. 3) .
DISCUSSION
In 1923 Stokes reported a naevus pilaris with hyperplasia of non-striated muscle (1) . This condition has since been given various names (2, 3) . Internationally, the term congenital smooth muscle hamartoma of the skin (CSMH) is now accepted.
The classical localized variant of CSMH shows a unilateral, hairy, hyperpigmented plaque on the trunk or on a proximal limb (2, 3) . Rubbing the lesion leads towards piloerection and a transiently increased ®rmness (pseudo Darier sign) (3). Another subentity of CSMH is characterized by a circumscribed annular patch with multiple follicular papules. Unlike classical CSMH, there is no hyperpigmentation and the hair pattern changes are less prominent (4) .
There have also been reports of patients with multiple CSMH (5) . Diffuse CSMH has been described as part of the Michelintyre-baby syndrome (6) . This syndrome is characterized by a combination of anomalies, such as ringed skin creases, cleft palate, epicanthal folds, hyperteleorism, malformed ears and developmental delay (6) .
On the basis of these criteria, we propose a clinical classi®cation of CSMH of the skin. (1) found a cumulative incidence of skin cancer, ranging from 10% to 40%, at 10 and 20 years after transplantation. Bouwes Bavinck et al. (2) , in a cohort of Australian patients, reported a higher incidence (from 45% to 70% at 10 and 20 years after transplantation), related to the more intense sun exposure at those latitudes. Only few reports have been published about RTRs from southern Europe and Italy. From 1990 to 1997 we enrolled a consecutive series of RTRs in a dermatological screening program, followed up by the Second Division of Surgery and Kidney Transplantation Centre of the Ospedale Civile Maggiore, Verona, Italy. All patients gave their informed consent before medical examination.
We examined 423 RTR subjects (290 males and 133 females), treated with 3 different immunosuppressive regimens: prednisolonezazathioprine (PA) (71 patients), prednisolonezazathioprinezcyclosporin (PAC) (191 patients), prednisolonezcyclosporin (PC) (161 patients). An accurate dermatological anamnesis was collected. Clinical records were available for all the patients. For each patient we recorded the following data: age, sex, stature, weight, date of the transplantation and of the visit, type and maintenance posology of the immunosuppressive drugs. The whole skin surface and mucous membranes were examined by a dermatologist. Any lesion suspected to be a skin cancer was excised and its histology examined. For estimates of potential prognostic factors, only variables available at the time of the transplant were considered: we took as an end point the diagnosis of cancer. Cox's proportional-hazards regression model (3), performing backward stepping of variables with pre-assigned p values equal to 0.05 that controlled the stepping removal, and Kaplan and Meir survival curves were carried out.
The mean age of the RTRs at the visit was 46.2 years (SD 11.2, age range 19 ± 68 years) and mean age at transplantation was 38.9 years (SD 11.7 age range 12 ± 65 years), with no difference between males and females. Mean follow-up time was 7.6 years (SD 5.38, range 0 ± 26 years): the PA group had a longer follow-up time (14.0 years) (SD 6.0) than the PAC group (6.6 years) (SD 3.9) and the PC group (5.9 years) (SD 4.7).
A total of 43 patients were excluded: 30 died of various accidents unrelated to the graft function and 13 rejected the graft (Table I) .
A skin cancer was detected in 21/423 patients (5%) (BCC 10; Bowen 2; Keratoacanthomas 3; SCC 6). Cumulative incidence of the ®rst cancer at 5, 10, 15 and 20 years of follow-up was 0.8%, 5.2%, 11.2% and 15.3%, respectively. The incidence of cancer was not signi®cantly different in the 3 
